ID

28831

Beschreibung

A Study of Infliximab for Treatment Resistant Major Depression; ODM derived from: https://clinicaltrials.gov/show/NCT00463580

Link

https://clinicaltrials.gov/show/NCT00463580

Stichworte

Versionen (1)
  1. 07.02.18 07.02.18 -
Rechteinhaber

See clinicaltrials.gov

Hochgeladen am

7. Februar 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Depression NCT00463580

Englisch

Eligibility Depression NCT00463580

1 Formulare  
  1. StudyEvent: Eligibility
    1. Eligibility Depression NCT00463580
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
1. males or females ages 25-60. must be able to read and understand english.
Beschreibung

Age | Able to read English Language | Comprehension English Language

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C0586740
UMLS CUI [2,2]
C0376245
UMLS CUI [3,1]
C0233733
UMLS CUI [3,2]
C0376245
2. currently meets dsm-iv criteria for a major depressive episode. (history of either unipolar major depression (depressive episodes only) or bipolar i disorder (history of manias and depressions) or bipolar ii disorder (hypomanias and depressions), current episode depressed acceptable).
Beschreibung

Single major depressive episode | Unipolar Depression | Bipolar I disorder | Mania | Depressive disorder | Bipolar II disorder | Depression with hypomania (bipolar 2)

Datentyp

boolean

Alias
UMLS CUI [1]
C0024517
UMLS CUI [2]
C0041696
UMLS CUI [3]
C0853193
UMLS CUI [4]
C0338831
UMLS CUI [5]
C0011581
UMLS CUI [6]
C0236788
UMLS CUI [7]
C1852199
3. must meet criteria for "treatment resistant" depression defined by failure to respond to, or intolerance of, at least 2 treatment trials (antidepressants or ect) during the current episode.
Beschreibung

Depressive Disorder, Treatment-Resistant | Therapeutic procedure Quantity Unresponsive to Treatment | Intolerance Therapeutic procedure | Antidepressive Agents | Electroconvulsive Therapy

Datentyp

boolean

Alias
UMLS CUI [1]
C2063866
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0205269
UMLS CUI [3,1]
C0231199
UMLS CUI [3,2]
C0087111
UMLS CUI [4]
C0003289
UMLS CUI [5]
C0013806
4. all subjects will be fully ambulatory and in good medical health.
Beschreibung

Ambulatory | General health good

Datentyp

boolean

Alias
UMLS CUI [1]
C0439841
UMLS CUI [2]
C1277245
5. are required to either be antidepressant free for 2 weeks prior to study entry (4 weeks for fluoxetine secondary to long half-life) or be on a fixed psychotropic medication regimen for at least 4 weeks. subjects and their primary care providers must agree to continue their status (i.e. without antidepressant or on a fixed regimen) until the 12-week assessment is complete.
Beschreibung

Antidepressive Agents Free of | Fluoxetine Free of | On psychotropic medication

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0003289
UMLS CUI [1,2]
C0332296
UMLS CUI [2,1]
C0016365
UMLS CUI [2,2]
C0332296
UMLS CUI [3]
C3874456
6. pre-menopausal female subjects must not be pregnant and must be willing to use adequate contraception during the study period.
Beschreibung

Premenopausal state Contraceptive methods | Pregnancy Absent

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0232969
UMLS CUI [1,2]
C0700589
UMLS CUI [2,1]
C0032961
UMLS CUI [2,2]
C0332197
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
1. current or history of psychotic symptoms.
Beschreibung

Psychotic symptom

Datentyp

boolean

Alias
UMLS CUI [1]
C0871189
2. active suicidal ideation (defined as a score of ≥3 on hdrs suicide item).
Beschreibung

Feeling suicidal Hamilton depression rating scale (HDRS)

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0424000
UMLS CUI [1,2]
C2021166
3. prior use of a tnf-alpha antagonist (i.e. etanercept, infliximab, adalimumab) and use of any other immunosuppressant agent (i.e. systemic corticosteroids or anti-proliferative agents such as methotrexate) within one year of study entry.
Beschreibung

Tumor necrosis factor alpha blockers | Etanercept | infliximab | adalimumab | Immunosuppressive Agents | CORTICOSTEROIDS FOR SYSTEMIC USE | Antineoplastic Agents | Methotrexate

Datentyp

boolean

Alias
UMLS CUI [1]
C2170827
UMLS CUI [2]
C0717758
UMLS CUI [3]
C0666743
UMLS CUI [4]
C1122087
UMLS CUI [5]
C0021081
UMLS CUI [6]
C3653708
UMLS CUI [7]
C0003392
UMLS CUI [8]
C0025677
4. current use of aspirin, non-steroidal anti-inflammatory agents (nsaids) or cox-2 inhibitors during the study. acetaminophen will be allowed.
Beschreibung

Aspirin | Anti-Inflammatory Agents, Non-Steroidal | Cyclooxygenase 2 Inhibitors | Acetaminophen allowed

Datentyp

boolean

Alias
UMLS CUI [1]
C0004057
UMLS CUI [2]
C0003211
UMLS CUI [3]
C1257954
UMLS CUI [4,1]
C0000970
UMLS CUI [4,2]
C0683607
5. history of any of the following conditions: congestive heart failure, abnormal electrocardiogram, malignancy, schizophrenia, neurological disease, auto-immune condition (e.g. rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, lupus), chronic infection (e.g. human immunodeficiency virus, hepatitis b or c), and hematologic, renal or hepatic abnormality.
Beschreibung

Congestive heart failure | Electrocardiogram abnormal | Malignant Neoplasms | Schizophrenia | Nervous system disorder | Autoimmune Diseases | Rheumatoid Arthritis | Inflammatory Bowel Diseases | Multiple Sclerosis | Lupus Erythematosus | Chronic infectious disease | HIV Infection | Hepatitis B | Hepatitis C | Abnormality Hematologic | Abnormality Kidney | Abnormality of the liver

Datentyp

boolean

Alias
UMLS CUI [1]
C0018802
UMLS CUI [2]
C0522055
UMLS CUI [3]
C0006826
UMLS CUI [4]
C0036341
UMLS CUI [5]
C0027765
UMLS CUI [6]
C0004364
UMLS CUI [7]
C0003873
UMLS CUI [8]
C0021390
UMLS CUI [9]
C0026769
UMLS CUI [10]
C0409974
UMLS CUI [11]
C0151317
UMLS CUI [12]
C0019693
UMLS CUI [13]
C0019163
UMLS CUI [14]
C0019196
UMLS CUI [15,1]
C1704258
UMLS CUI [15,2]
C0205488
UMLS CUI [16,1]
C1704258
UMLS CUI [16,2]
C0022646
UMLS CUI [17]
C4021780
6. subjects will be excluded for a positive anti-double stranded dna antibody test.
Beschreibung

Serum double-stranded DNA antibody measurement Positive

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2229702
UMLS CUI [1,2]
C1514241
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Depression NCT00463580

1 Formulare
  1. StudyEvent: Eligibility
    1. Eligibility Depression NCT00463580
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
Age | Able to read English Language | Comprehension English Language
Item
1. males or females ages 25-60. must be able to read and understand english.
boolean
C0001779 (UMLS CUI [1])
C0586740 (UMLS CUI [2,1])
C0376245 (UMLS CUI [2,2])
C0233733 (UMLS CUI [3,1])
C0376245 (UMLS CUI [3,2])
Single major depressive episode | Unipolar Depression | Bipolar I disorder | Mania | Depressive disorder | Bipolar II disorder | Depression with hypomania (bipolar 2)
Item
2. currently meets dsm-iv criteria for a major depressive episode. (history of either unipolar major depression (depressive episodes only) or bipolar i disorder (history of manias and depressions) or bipolar ii disorder (hypomanias and depressions), current episode depressed acceptable).
boolean
C0024517 (UMLS CUI [1])
C0041696 (UMLS CUI [2])
C0853193 (UMLS CUI [3])
C0338831 (UMLS CUI [4])
C0011581 (UMLS CUI [5])
C0236788 (UMLS CUI [6])
C1852199 (UMLS CUI [7])
Depressive Disorder, Treatment-Resistant | Therapeutic procedure Quantity Unresponsive to Treatment | Intolerance Therapeutic procedure | Antidepressive Agents | Electroconvulsive Therapy
Item
3. must meet criteria for "treatment resistant" depression defined by failure to respond to, or intolerance of, at least 2 treatment trials (antidepressants or ect) during the current episode.
boolean
C2063866 (UMLS CUI [1])
C0087111 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0231199 (UMLS CUI [3,1])
C0087111 (UMLS CUI [3,2])
C0003289 (UMLS CUI [4])
C0013806 (UMLS CUI [5])
Ambulatory | General health good
Item
4. all subjects will be fully ambulatory and in good medical health.
boolean
C0439841 (UMLS CUI [1])
C1277245 (UMLS CUI [2])
Antidepressive Agents Free of | Fluoxetine Free of | On psychotropic medication
Item
5. are required to either be antidepressant free for 2 weeks prior to study entry (4 weeks for fluoxetine secondary to long half-life) or be on a fixed psychotropic medication regimen for at least 4 weeks. subjects and their primary care providers must agree to continue their status (i.e. without antidepressant or on a fixed regimen) until the 12-week assessment is complete.
boolean
C0003289 (UMLS CUI [1,1])
C0332296 (UMLS CUI [1,2])
C0016365 (UMLS CUI [2,1])
C0332296 (UMLS CUI [2,2])
C3874456 (UMLS CUI [3])
Premenopausal state Contraceptive methods | Pregnancy Absent
Item
6. pre-menopausal female subjects must not be pregnant and must be willing to use adequate contraception during the study period.
boolean
C0232969 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0032961 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
Item Group
C0680251 (UMLS CUI)
Psychotic symptom
Item
1. current or history of psychotic symptoms.
boolean
C0871189 (UMLS CUI [1])
Feeling suicidal Hamilton depression rating scale (HDRS)
Item
2. active suicidal ideation (defined as a score of ≥3 on hdrs suicide item).
boolean
C0424000 (UMLS CUI [1,1])
C2021166 (UMLS CUI [1,2])
Tumor necrosis factor alpha blockers | Etanercept | infliximab | adalimumab | Immunosuppressive Agents | CORTICOSTEROIDS FOR SYSTEMIC USE | Antineoplastic Agents | Methotrexate
Item
3. prior use of a tnf-alpha antagonist (i.e. etanercept, infliximab, adalimumab) and use of any other immunosuppressant agent (i.e. systemic corticosteroids or anti-proliferative agents such as methotrexate) within one year of study entry.
boolean
C2170827 (UMLS CUI [1])
C0717758 (UMLS CUI [2])
C0666743 (UMLS CUI [3])
C1122087 (UMLS CUI [4])
C0021081 (UMLS CUI [5])
C3653708 (UMLS CUI [6])
C0003392 (UMLS CUI [7])
C0025677 (UMLS CUI [8])
Aspirin | Anti-Inflammatory Agents, Non-Steroidal | Cyclooxygenase 2 Inhibitors | Acetaminophen allowed
Item
4. current use of aspirin, non-steroidal anti-inflammatory agents (nsaids) or cox-2 inhibitors during the study. acetaminophen will be allowed.
boolean
C0004057 (UMLS CUI [1])
C0003211 (UMLS CUI [2])
C1257954 (UMLS CUI [3])
C0000970 (UMLS CUI [4,1])
C0683607 (UMLS CUI [4,2])
Congestive heart failure | Electrocardiogram abnormal | Malignant Neoplasms | Schizophrenia | Nervous system disorder | Autoimmune Diseases | Rheumatoid Arthritis | Inflammatory Bowel Diseases | Multiple Sclerosis | Lupus Erythematosus | Chronic infectious disease | HIV Infection | Hepatitis B | Hepatitis C | Abnormality Hematologic | Abnormality Kidney | Abnormality of the liver
Item
5. history of any of the following conditions: congestive heart failure, abnormal electrocardiogram, malignancy, schizophrenia, neurological disease, auto-immune condition (e.g. rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, lupus), chronic infection (e.g. human immunodeficiency virus, hepatitis b or c), and hematologic, renal or hepatic abnormality.
boolean
C0018802 (UMLS CUI [1])
C0522055 (UMLS CUI [2])
C0006826 (UMLS CUI [3])
C0036341 (UMLS CUI [4])
C0027765 (UMLS CUI [5])
C0004364 (UMLS CUI [6])
C0003873 (UMLS CUI [7])
C0021390 (UMLS CUI [8])
C0026769 (UMLS CUI [9])
C0409974 (UMLS CUI [10])
C0151317 (UMLS CUI [11])
C0019693 (UMLS CUI [12])
C0019163 (UMLS CUI [13])
C0019196 (UMLS CUI [14])
C1704258 (UMLS CUI [15,1])
C0205488 (UMLS CUI [15,2])
C1704258 (UMLS CUI [16,1])
C0022646 (UMLS CUI [16,2])
C4021780 (UMLS CUI [17])
Serum double-stranded DNA antibody measurement Positive
Item
6. subjects will be excluded for a positive anti-double stranded dna antibody test.
boolean
C2229702 (UMLS CUI [1,1])
C1514241 (UMLS CUI [1,2])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video